Out now: “Getting Data to Grow in a Dish,” the third issue of Deep Phenotype, insitro’s Substack on scaled biology and deep causality.
Generating biological data at scale is one challenge. Ensuring that data is reliable, reproducible and meaningful enough to power AI-driven drug
At insitro, we proved again we don't spook easy at our annual Halloween costume contest last week. Every team that participated shared the same stretch goal: win.
Protein Sciences modeled the central dogma of molecular biology with paper bases and arrows. Read the costumes from
Pattern recognition tells you what’s associated with disease, not what drives it. At #AIDDD2026, insitro CSO Philip Tagari presents “Generative AI for Target Hypothesis Design: Moving Beyond Pattern Recognition,” plus Workshop 5 on building techbio at scale, Oct 27.
Today, insitro announced a strategic collaboration with @AstraZeneca for the AI-enabled discovery of novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.
insitro will receive $40 million upfront and is eligible for up to
@insitro is proud to announce that biotech companies in the Lilly TuneLab™ network can now deploy advanced machine learning models built by insitro with @EliLillyandCo to predict in vitro and, critically, in vivo properties of small molecules — representing collective progress
